[1] PETIT AM, RAK J, HUNG MC, et al.Neutralizing antibodies againstepidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy ofsolid tumors[J]. Am J Pathol, 1997, 151(6): 1523-1530. [2] ETTINGER DS, WOOD DE, AISNER DL, et al.NCCN guidelinesinsights: non-small cell lung cancer, version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266. [3] TAMURA M, TAKAI Y, NAKAMURA S, et al.A case report of pseudo-exfoliation syndrome with prolonged corneal epithelial regeneration because of erlotinib-induced unilateral corneal ulcer and anterior uveitis[J]. Acta Ophthalmol, 2020, 98(8): e1055-e1056. [4] BRADEN RL, ANADKAT MJ.EGFR inhibitor-induced skinreactions: differentiating acneiform rash from superimposed bacterial infections[J]. Support Care Cancer, 2016, 24(9): 3943-3950. [5] LACOUTURE ME.Mechanisms of cutaneous toxicities to EGFRinhibitors[J]. Nat Rev Cancer, 2006, 6(10): 803-812. [6] OWCZAREK W, SŁOWIŃSKA M, LESIAK A, et al. The incidenceand management of cutaneous adverse events of the epidermal growth factor receptor inhibitors[J]. Postepy Dermatol Alergol, 2017, 34(5): 418-428. [7] BORKAR DS, LACOUTURE ME, BASTI S.Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review[J]. Support Care Cancer, 2013, 21(4): 1167-1174. [8] CHOI HD, CHANG MJ.Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: a meta- analysis[J]. PLoS One, 2020, 15(7): e0234818. [9] ENDO-TSUKUDE C, SASAKI JI, SAEKI S, et al.Population Pharmacokinetics and adverse events of erlotinib in japanese patients with non-small-cell lung cancer: impact of genetic polymorphisms in metabolizing enzymes and transporters[J]. Biol Pharm Bull, 2018, 41(1): 47-56. [10] MUELLER-SCHOELL A, GROENLAND SL, SCHERF-CLAVELO, et al.Therapeutic drug monitoring of oral targeted antineoplastic drugs published correction appears in Eur J Clin Pharmacol[J]. Eur J Clin Pharmacol, 2021, 77(4): 441-464. [11] LU JF, EPPLER SM, WOLF J, et al.Clinical pharmacokineticsof erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer[J]. Clin Pharmacol Ther, 2006, 80(2): 136-145. [12] BIGOT F, BOUDOU-ROUQUETTE P, ARRONDEAU J, et al.Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old[J]. Investigational New Drugs: The Journal of New Anticancer Agents, 2017, 35(2): 242-246. [13] NANNEY LB, MAGID M, STOSCHECK CM, et al.Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages[J]. J Invest Dermatol, 1984, 83(5): 385-393. [14] CHARALAMBOUS A.Living with the effects of cutaneous toxicities induced by treatment[J]. Asia Pac J Oncol Nurs, 2017 , 4(3): 220-223. [15] LIU Z, CARVAJAL M, CARRAWAY CA, et al.Expression ofthe receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in humanocularsurfaceepithelia[J]. Cornea, 2001, 20(1): 81-85. [16] NA NNEY LB, STOSCHECK CM, KING LE JR, et al.Immunolocalization of epidermal growth factor receptors in normal developing human skin[J]. J Invest Dermatol, 1990, 94(6): 742-748. [17] CIESKE JD, TAKAHASHI H, HUTCHEON AE, et al.Activation of epidermal growth factor receptor during corneal epithelial migration[J]. Invest Ophthalmol Vis Sci, 2000, 41(6): 1346-1355. [18] PETERSON JL, CERESA BP.Epidermal growth factor receptor expression in the corneal epithelium[J]. Cells, 2021, 10(9): 2409. |